Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced that four individual abstracts for Triferic have been selected by the ERA-EDTA Congress for presentation May 28-31, 2015 in London, UK. Triferic is the Company’s recent FDA-approved iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.

The following abstracts will be presented at the ERA-EDTA Congress:

  • Triferic Administered via Dialysate Maintains Iron Balance and Hemoglobin: Phase 3 Study Results (Oral Presentation in Free communication session: Anemia – Novel approaches; Friday May 29 at 11:45 AM)
  • Structural, Physical and Functional Characterization of Ferric Pyrophosphate Citrate (FPC, Triferic), A Novel Iron Compound for Pharmaceutical Applications (Poster Session Friday May 29 FP 673)
  • Triferic Has a Safety Profile Similar to Placebo: An Integrated Safety Analysis of Phase 2 and 3 Studies (Poster Session Friday May 29 FP 654)
  • Pharmacokinetics of Triferic Administered IV to Healthy Volunteers: No Effect on Hepcidin or Oxidative Stress Markers (Poster Session Sat May 30 SP 394)

ERA-EDTA is one of the fastest growing Medical Associations, whose purpose is to encourage and to report advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects. (Original Source)

Shares of Rockwell Medical closed yesterday at $10.5 . RMTI has a 1-year high of $12.47 and a 1-year low of $8.10. The stock’s 50-day moving average is $10.41 and its 200-day moving average is $10.08.

On the ratings front, Rockwell Medical has been the subject of a number of recent research reports. In a report issued on February 27, Brean Murray Carret analyst Jonathan Aschoff maintained a Sell rating on RMTI, with a price target of $4, which represents a potential downside of 61.9% from where the stock is currently trading. Separately, on January 27, Oppenheimer’s Ling Wang reiterated a Buy rating on the stock and has a price target of $26.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and Ling Wang have a total average return of 6.8% and -4.9% respectively. Aschoff has a success rate of 51.9% and is ranked #521 out of 3599 analysts, while Wang has a success rate of 31.4% and is ranked #3273.

Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.